Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director | August 20, 2024 | August 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date August 20, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2034-08-20 | Direct | 125,000 |
Reported balance
After 2024-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-20 · Grant · Acquired 125,000 · Balance 125,000 F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2024 Filed Aug 22, 2024 22:05 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001493152-24-033623 · ownership.xml · derivative · entry 1 Rendall David · CIK 0001869521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-08-20 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:23 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-23-044441 · doc4.xml · derivative · entry 1 Rendall David · CIK 0001869521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2025 or January 15, 2025. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:39 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001209191-22-052270 · doc4.xml · derivative · entry 1 Rendall David · CIK 0001869521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-09-30 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:17 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 325,000 | $0.15 | $48,750.00 |
DisclosureSEC source: 0001209191-22-042562 · doc4.xml · nonDerivative · entry 1 Rendall David · CIK 0001869521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,371 F1 · kind: This transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors. Read SEC document |
| June 18, 2021 Filed Jun 24, 2021 23:36 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-21-043164 · doc4.xml · derivative · entry 1 Rendall David · CIK 0001869521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.